Results for this period
First quarter1 June 2026 to 31 August 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Operating income declined due to lower net sales, increased inventory write-downs and higher raw material costs driven by the weaker yen. For active pharmaceutical ingredients, sales of antitussives for OTC medicines and anti-inflammatory analgesics for generic medicines declined, while for finished formulations, sales of generic and OTC products declined.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 June 2026 to 31 August 2026 |
| Net Sales | ¥11,894 million (YoY -8.6%) |
| Operating profit | ¥712 million (YoY -28.7%) |
| Ordinary income | ¥808 million (YoY -23.2%) |
| Profit attributable to owners of the parent | ¥700 million (YoY +0.6%) |
| Net income per share | ¥24.66 |
| Equity ratio | End of the current fiscal period 73.2 / End of previous period 72.2 |
| Total assets | ¥71,646 million |
| Net assets | ¥52,483 million |
| Full-year earnings forecast | Net Sales ¥54,000 million (YoY +6.6%) / Operating profit ¥4,000 million (YoY +10.0%) / Ordinary income ¥4,000 million (YoY +4.9%) / Net income ¥3,000 million (YoY -5.1%) |
| Annual Dividend Forecast | ¥40 → ¥45（+12.5%） |
| Depreciation and amortization | ¥975 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Subsidy Income ¥96 million, Gain on sale of investment securities ¥145 million / Extraordinary loss Loss on Disposal of Fixed Assets ¥0 million, Loss on reduction of fixed assets ¥86 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 28,854,880 Shares |
| Treasury Shares at Period-End | 595,058 Shares |
| Factors Behind Changes in Business Performance | Operating income declined due to lower net sales, increased inventory write-downs and higher raw material costs driven by the weaker yen. For active pharmaceutical ingredients, sales of antitussives for OTC medicines and anti-inflammatory analgesics for generic medicines declined, while for finished formulations, sales of generic and OTC products declined. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Operating income and ordinary income declined due to lower net sales, increased inventory write-downs and higher raw material costs driven by the weaker yen. For active pharmaceutical ingredients, sales of antitussives and anti-inflammatory analgesics declined, while for finished formulations, sales of generic and OTC products declined.